Biolife Solutions, Inc. · NASDAQ:BLFS
Biolife Solutions — Investor Presentation (February 2017)
43 slides from Biolife Solutions's investor presentation, Feb 16, 2017
Slide 1: Biopreservation Tools for Cells, Tissues and Organs
NASDAQ: BLFS Corporate Presentation February 2017 Biopreservation Tools for Cells, Tissues and Organs
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward - looking statements, including, but not limited to, statements concerning the company’s anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, new
Slide 3: Mission
Mission Become the leading provider of biopreservation tools for cells, tissues, and organs; By supplying best in class tools for maintaining the health and function of biologic source material and finished products during manufacturing, storage and distribution. 3 WHAT WHY HOW To facilitate basic a
Slide 4: Executive Team
4 Executive Team: 200 Years Experience Mike Rice – Chief Executive Officer BS Bus Admin; 10 years as BLFS CEO; chief visionary of BLFS market opportunities, branding, marketing strategies; 18 years medical device sales, sales management, marketing; patient monitoring, defibrillators, implantable CRM
Slide 5: Our Biopreservation Tools
5 Our Biopreservation Tools Media designed to preserve biologics during ex vivo storage and shipment Goal: maximize effectiveness of biologic based medicine Smart, cloud - connected shipping containers engineered to maintain stability of time and temperature sensitive biologic materials from vein to
Slide 6: Worldwide Customer Base
Worldwide Customer Base 392 • 33 Countries • 530 Direct Customers • Excludes Distributor End Customers 21 61 15 8 24 6 3 6 © 2017 BIOLIFE SOLUTIONS, INC.
Slide 7: Executing to Drive Growth
7 Executing to Drive Growth >500 CUSTOMERS >250 REGEN MED APPLICATIONS PRODUCT ADOPTION 2016 RECORD REVENUE OF $8.2MM 28% YoY GROWTH 250 PUBLISHED PAPERS, POSTERS and ABSTRACTS EVIDENCE © 2017 BIOLIFE SOLUTIONS, INC.
Slide 8: Preservation of Biologic Material
8 Preservation of Biologic Material Solid Organs Tumor Tissue Biopsies Apheresis Bone Marrow Allogeneic Transplant Biobanking Drug Discovery Regenerative Medicine Autologous Cell Therapy © 2017 BIOLIFE SOLUTIONS, INC.
Slide 9: Biopreservation Challenges
9 Biopreservation Challenges Survival – How Long Viability – How Much Function – How Well Ex Vivo Time Viability Ex Vivo Time Survival Ex Vivo Time Function Cold storage is used to preserve biologic integrity and function by lowering metabolism . When removed from the body – cells, tissues, and orga
Slide 10: Improved Cell Yield - Lower COGS
10 Improved Cell Yield - Lower COGS Yield Yield Cost Cost LESS Required to Achieve Desired Therapeutic Effect Source Material Manufactured Cell Products LESS Required MORE Doses = © 2017 BIOLIFE SOLUTIONS, INC.
Slide 11: CryoStor Freeze Media
Serum - free, protein - free, animal origin free; highest quality ingredients; US FDA Master File 11 CryoStor® Freeze Media Improved cell viability and functional recovery compared to commercial and home - brew alternatives in numerous cell types Formulated to mitigate molecular cell stress during f
Slide 12: HypoThermosol Storage Media
12 HypoThermosol® Storage Media Optimized for hypothermic (2 - 8 ° C) storage and shipping of cells and tissues Enables multiple days of cell and tissue storage for transport of source material and manufactured cell products throughout the world Serum - free, protein - free, animal origin free; USP
Slide 13: Product Performance
Cells Preserved in traditional “home brew” Human mesenchymal stem cells isolated from bone marrow; condition of cells after 5 days of cold storage, then returned to culture conditions and assayed 24 hours later 13 Product Performance Cells Preserved in HypoThermosol ® Dead cells Healthy cells © 2017
Slide 14: Over Articles, Abstracts & Posters
14 Over 250 Articles, Abstracts & Posters © 2017 BIOLIFE SOLUTIONS, INC.
Slide 15: Biopreservation Market
15 Biopreservation Market Source : Biopreservation Market Size By Product (Equipment, Media, Laboratory Information Management System), By Application (Regenerative Medicine, Biobanking, Drug Discovery), Industry Analysis Report, Regional Outlook (U . S . , Canada, UK, Germany, Japan, China, Brazil,
Slide 16: Strategic Revenue Markets
16 3 Strategic Revenue Markets REGENERATIVE MEDICINE C ell therapy companies Hospital - based stem cell transplant centers University - based clinical research labs Cell therapy CDMO, CRO DRUG DISCOVERY Pharmaceutical companies Cell suppliers Toxicity testing labs Personalized medicine labs BIOBANKI
Slide 17: Regenerative Medicine Opportunity
Regenerative Medicine Opportunity 17 © 2017 BIOLIFE SOLUTIONS, INC.
Slide 18: Regen Med Market Investments
18 Regen Med Market Investments © 2017 BIOLIFE SOLUTIONS, INC.
Slide 19: Vein to Vein Customer Engagement
19 Vein to Vein Customer Engagement Source Material Preservation Media Cell Factory Manufactured Products Temperature Controlled Container Preservation Media 4 Engagement Opportunities : Media and Cold Chain for Source Material and Final Dose Patient Temperature Controlled Container Temperature Cont
Slide 20: Customers Targeting All Major Disease States
Customers Targeting All Major Disease States 20 © 2017 BIOLIFE SOLUTIONS, INC. Immune Stroke Cardiac Diabetes HIV OA PAD CLI GVHD Cancer Kidney Disease ALZ Spinal >250 REGEN MED APPLICATIONS
Slide 21: Marquee Customers
21 Marquee Customers DISTRIBUTORS CMO & CDMO DIRECT – 100 REGEN MED COMPANIES © 2017 BIOLIFE SOLUTIONS, INC.
Slide 22: Engagement Strength
Engagement Strength “Over the last several years we have worked to qualify and adopt CryoStor in our clinical manufacturing process. We are now securing long term supply continuity for this reagent as our cell therapy product candidate continues to progress through multiple clinical trials." Marc Be
Slide 23: Significant Growth Potential
23 Significant Growth Potential Annual BioLife Revenue Per Customer Approval: $500,000 - $2,000,000 X = X X X X X = = Annual Doses Produced BioLife Product Used Per Dose (mL) Price per mL Annual Revenue Rare Cancer (2.5K) Common Cancer (10K) Osteoarthritis (200K) X X = 3.5ml $3.00 $2.1M 60ml $3.00 $
Slide 24: Intelligent, Informed, Precise Biologic Materials Management
Intelligent, Informed, Precise Biologic Materials Management e vo ® Cold Chain 2.0™ Cloud - Based Cold Chain Management 24 © 2017 BIOLIFE SOLUTIONS, INC.
Slide 25: Vertical SaaS for Cold Chain Management
Patents Pending 25 Vertical SaaS for Cold Chain Management © 2017 BIOLIFE SOLUTIONS, INC.
Slide 26: Cloud-Connected Smart Shippers
2 - 8 ° C Use with pre - conditioned cold packs 26 Cloud - Connected Smart Shippers CRT 15 ° C - 20 ° C Use with pre - conditioned cold packs CRYO - 80 ° C Use with dry ice Patents Pending © 2017 BIOLIFE SOLUTIONS, INC.
Slide 27: evo System Performance
e vo® System Performance "We have been extremely pleased with the performance of the evo® Cold Chain 2 . 0 ™ system for use in our phase 3 study . The unique uni - directional packout prevents errors in packaging and makes it very simple for our clinical sites to package the starting apheresis produ
Slide 28: biologistex JV Restructuring
b iologistex JV Restructuring • All evo® Smart Shipper and biologistex™ Cold Chain SaaS IP and assets now consolidated in one entity to enable additional direct investment in the JV; not via BLFS stock offering • BioLife is the exclusive distributor to the worldwide regen med market • BioLife holds
Slide 29: Financial Information
Financial Information 29 © 2017 BIOLIFE SOLUTIONS, INC.
Slide 30: Biopreservation Media Revenue Growth
Biopreservation Media Revenue Growth $0 $500,000 $1,000,000 $1,500,000 $2,000,000 $2,500,000 1Q12 2Q12 3Q12 4Q12 1Q13 2Q13 3Q13 4Q13 1Q14 2Q14 3Q14 4Q14 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 29% CAGR 2012 – 2016 30 © 2017 BIOLIFE SOLUTIONS, INC.
Slide 31: 2017 Catalysts
2017 Catalysts • Cell therapy customers, including Kite Pharma, are expected to receive regulatory approvals to commence marketing and commercial manufacturing, which, as a result, should drive increased demand for our proprietary biopreservation media products. • Continued adoption of CryoStor® and
Slide 32: 2017 Guidance
2017 Guidance • Biopreservation media revenue growth of 20% - 25% over 2016; revenue in excess of $10 million • Gross margin in a range of 55% to 60% • Operating expenses ranging from $8 - $9 million, reflecting a quarterly decrease of $400,000 - $500,000 resulting from the restructuring of the biol
Slide 33: Operating Leverage
Operating Leverage • Two independent cGMP formulation and fill suites • 100,000 liter annual capacity in current facilities • No significant CAPEX required to realize 10X current production level • Potential 10 + percentage point gross margin increase as demand ramps • Minimal SG&A expense increases
Slide 34: Capitalization Table
Capitalization Table 34 ▪ 6.9M priced at $4.75 ▪ 4.0M held by the same two long term shareholders ▪ Management and employee incentives ▪ 1.6M vested ▪ $1.83 wt. avg exercise price ▪ Limited institutional holders ▪ 48% held by two long term shareholders Shares – 13.3M Directors & Officers Affiliates
Slide 35: Share Price
Share Price © 2017 BIOLIFE SOLUTIONS, INC. 35 0 50,000 100,000 150,000 200,000 250,000 300,000 350,000 400,000 450,000 500,000 $0.00 $0.50 $1.00 $1.50 $2.00 $2.50 1/1/16 2/1/16 3/1/16 4/1/16 5/1/16 6/1/16 7/1/16 8/1/16 9/1/16 10/1/16 11/1/16 12/1/16 1/1/17 2/1/17 Volume Price
Slide 36: Contact
NASDAQ: BLFS For additional questions or comments, please contact: Mike Rice | President and CEO [email protected] | (425) 686 - 6003 Roderick de Greef | CFO [email protected] | (425) 686 - 6002 www.biolifesolutions.com BioLife Solutions, Inc. 3303 Monte Villa Parkway, Suite 310
Slide 37: Supplemental Slides
Supplemental Slides 37 © 2017 BIOLIFE SOLUTIONS, INC.
Slide 38: evo Smart Shipper
38 evo™ Smart Shipper Integrated cell phone with real time location and payload monitoring via SaaS Durable and reusable – designed for harsh small parcel shipping environment Intuitive, universal pack - out; ALL SEASON™ Cold Packs; eliminates packout errors True payload temp monitored via integrate
Slide 39: The Problem: Cell Therapy Dynamics
The Problem: Cell Therapy Dynamics • Traditional pharma – bulk manufacturing: • 80 million to 130 million annual temperature sensitive shipments requiring cold chain logistics 1 • $12 billion spent annually on cold chain logistics, with $9 billion for transportation and $3 billion for specialized te
Slide 40: Competitive Shippers: Inadequate Foam Coolers
40 Competitive Shippers: Inadequate Foam Coolers • Old technology • Marginal performance • Single - use Data Loggers • Records container, not payload temperature • Data reviewed after clinical product is used Vacuum Panel Shippers • Overly complex • Heavy, expensive to ship • Prone to packout errors
Slide 41: Risks – Broken Cold Chain
41 Risks – Broken Cold Chain Economic Cost of scrapping biologic source material or manufactured cell products Clinical trial impact from poor biologistics management; lost doses, poor shipping container performance, temperature excursions, trial failure, funding exposure, reimbursement exposure $ C
Slide 42: Cloud Based – Integrated Logistics
42 Cloud Based – Integrated Logistics Single app enables simple logistics: Cloud Hosted, Secure SaaS 21 CFR Part 11 Auditable EVO # 31099282738 Alert: Package is within 5 miles of destination as of 5/5/2015 at 21:19PST • biologistex • Shipment 494839 Picked up by carrier • biologistex • Shipment 494
Slide 43: Biologistics Addressable Market
Source: Pharmaceutical Commerce 2015, Management Estimates 43 Biologistics Addressable Market $500 Million Estimated Addressable Market for Cold Chain Shipping Containers and Data Loggers for Small Payloads and Individualized Cell Therapies $2.6B $500M Small Payload Containers & Data Loggers Medium/
Biolife Solutions — Investor Presentation (February 2017) on 6ix